Display options
Cite
Kim JY, Lee KH, Eisenhut M, et al. Efficacy of Cancer Immunotherapy: An Umbrella Review of Meta-analyses of Randomized Controlled Trials. Cancers (Basel). 2019;11(11)doi: 10.3390/cancers11111801.
Kim, J. Y., Lee, K. H., Eisenhut, M., van der Vliet, H. J., Kronbichler, A., Jeong, G. H., Shin, J. I., & Gamerith, G. (2019). Efficacy of Cancer Immunotherapy: An Umbrella Review of Meta-analyses of Randomized Controlled Trials. Cancers, 11(11), . https://doi.org/10.3390/cancers11111801
Kim, Jong Yeob, et al. "Efficacy of Cancer Immunotherapy: An Umbrella Review of Meta-analyses of Randomized Controlled Trials." Cancers vol. 11,11 (2019). doi: https://doi.org/10.3390/cancers11111801
Kim JY, Lee KH, Eisenhut M, van der Vliet HJ, Kronbichler A, Jeong GH, Shin JI, Gamerith G. Efficacy of Cancer Immunotherapy: An Umbrella Review of Meta-analyses of Randomized Controlled Trials. Cancers (Basel). 2019 Nov 15;11(11). doi: 10.3390/cancers11111801. PMID: 31731818; PMCID: PMC6895783.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2019 Nov 15;11(11). doi: 10.3390/cancers11111801.

Efficacy of Cancer Immunotherapy: An Umbrella Review of Meta-analyses of Randomized Controlled Trials.

Cancers

Jong Yeob Kim, Keum Hwa Lee, Michael Eisenhut, Hans J van der Vliet, Andreas Kronbichler, Gwang Hun Jeong, Jae Il Shin, Gabriele Gamerith

Affiliations

  1. Yonsei University College of Medicine, Seoul 03722, Korea.
  2. Department of Pediatrics, Yonsei University College of Medicine, Yonsei-ro 50, Seodaemun-gu, C.P.O. Box 8044, Seoul 03722, Korea.
  3. Children's & Adolescent Services, Luton & Dunstable University Hospital NHS Foundation Trust, Lewsey Road, Luton LU4 ODZ, UK.
  4. Department of Medical Oncology, VU University Medical Center, Cancer Center Amsterdam, 1081 HV Amsterdam, The Netherlands.
  5. Department of Internal Medicine IV (Nephrology and Hypertension), Medical University Innsbruck, Anichstraße 35, 6020 Innsbruck, Austria.
  6. College of Medicine, Gyeongsang National University, Jinju 52727, Korea.
  7. Department of Internal Medicine V (Hematology & Oncology), Medical University Innsbruck, Anichstraße 35, 6020 Innsbruck, Austria.

PMID: 31731818 PMCID: PMC6895783 DOI: 10.3390/cancers11111801

Abstract

We conducted a systematic review for evidence of the clinical efficacy of cancer immunotherapies. We searched PubMed from inception to 14 February 2018 for meta-analyses of randomized controlled trials (RCTs) of cancer immunotherapies. Re-analyses were performed to estimate the summary effect size under random-effects, the 95% confidence interval (CI), heterogeneity, and the 95% prediction interval, and we determined the strength of the evidence. We examined publication bias and excess significance bias. 63 articles corresponding to 247 meta-analyses were eligible. Nine meta-analyses were classified to have convincing evidence, and 75 were classified as suggestive evidence. The clinical benefit of immunotherapy was supported by convincing evidence in the following settings: anti-PD-1/PD-L1 monoclonal antibody (mAb) therapy for treating advanced melanoma and non-small cell lung cancer (NSCLC), the combination of rituximab and chemotherapy for treating chronic lymphocytic leukemia and B-cell non-Hodgkin's lymphoma, adoptive cell immunotherapy for NSCLC, and the combination of interferon α and chemotherapy for metastatic melanoma. A further meta-analysis of 16 RCTs showed that anti-PD-1/PD-L1 mAb therapy had a benefit in patients with solid tumors (overall survival; hazard ratio = 0.73, 95% CI: 0.68-0.79;

Keywords: cancer; immunotherapy; meta-analysis; umbrella review

Conflict of interest statement

The authors declare no conflicts of interest.

References

  1. J Clin Invest. 2015 Sep;125(9):3401-12 - PubMed
  2. Int J Epidemiol. 2010 Jun;39(3):932; author reply 933 - PubMed
  3. Behav Res Methods. 2009 Nov;41(4):1149-60 - PubMed
  4. J Thorac Dis. 2017 Mar;9(3):655-665 - PubMed
  5. Ann Intern Med. 2009 Aug 18;151(4):264-9, W64 - PubMed
  6. Saudi Med J. 2011 Jul;32(7):675-8 - PubMed
  7. Lancet Neurol. 2015 Mar;14(3):263-73 - PubMed
  8. Arch Gen Psychiatry. 2011 Aug;68(8):773-80 - PubMed
  9. Clin Trials. 2007;4(3):245-53 - PubMed
  10. Oncotarget. 2014 Dec 30;5(24):12472-508 - PubMed
  11. Postgrad Med. 2015 May;127(4):359-67 - PubMed
  12. Chin J Cancer. 2010 Jul;29(7):641-8 - PubMed
  13. BMJ. 1997 Sep 13;315(7109):629-34 - PubMed
  14. P T. 2017 Jun;42(6):375-383 - PubMed
  15. Oncotarget. 2017 May 31;8(35):59901-59914 - PubMed
  16. J R Stat Soc Ser A Stat Soc. 2009 Jan;172(1):137-159 - PubMed
  17. J Exp Med. 1991 Jul 1;174(1):139-49 - PubMed
  18. Acta Oncol. 2010;49(1):3-12 - PubMed
  19. Lancet Oncol. 2018 Jun;19(6):737-746 - PubMed
  20. BMJ. 2011 Feb 10;342:d549 - PubMed
  21. Nature. 2011 Dec 21;480(7378):480-9 - PubMed
  22. BMJ Open. 2016 Jul 12;6(7):e010247 - PubMed
  23. J Biomed Sci. 2017 Apr 4;24(1):26 - PubMed
  24. Oncoimmunology. 2017 Feb 21;6(4):e1294299 - PubMed
  25. J Natl Cancer Inst. 2007 May 2;99(9):706-14 - PubMed
  26. BMJ. 2008 May 3;336(7651):995-8 - PubMed
  27. BMJ. 2007 Nov 3;335(7626):914-6 - PubMed
  28. BMJ. 2011 Jul 22;343:d4002 - PubMed

Publication Types